BR0104586A - Método para tratamento de neurodegeneração - Google Patents

Método para tratamento de neurodegeneração

Info

Publication number
BR0104586A
BR0104586A BR0104586-5A BR0104586A BR0104586A BR 0104586 A BR0104586 A BR 0104586A BR 0104586 A BR0104586 A BR 0104586A BR 0104586 A BR0104586 A BR 0104586A
Authority
BR
Brazil
Prior art keywords
neurodegeneration
recovery
improvement
pharmaceutical compositions
treating neurodegeneration
Prior art date
Application number
BR0104586-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0104586A publication Critical patent/BR0104586A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BR0104586-5A 2000-02-23 2001-02-23 Método para tratamento de neurodegeneração BR0104586A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23
PCT/JP2001/001342 WO2001062246A1 (en) 2000-02-23 2001-02-23 Method for treating neurodegeneration

Publications (1)

Publication Number Publication Date
BR0104586A true BR0104586A (pt) 2002-01-08

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0104586-5A BR0104586A (pt) 2000-02-23 2001-02-23 Método para tratamento de neurodegeneração

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
KR100232929B1 (ko) 1995-07-10 1999-12-01 히로지 코데라 가공 선재의 접속 장치
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
ES2185963T3 (es) 1996-07-30 2003-05-01 Ecolab Gmbh & Co Ohg Agente filmogeno para la proteccion contra infecciones.
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제

Also Published As

Publication number Publication date
US20020055534A1 (en) 2002-05-09
IL145799A (en) 2006-10-31
AU3414501A (en) 2001-09-03
ES2270981T3 (es) 2007-04-16
DK1171123T3 (da) 2006-12-04
ID30377A (id) 2001-11-29
IL145799A0 (en) 2002-07-25
WO2001062246A1 (en) 2001-08-30
KR20010110798A (ko) 2001-12-13
AU784418B2 (en) 2006-03-30
NO20015162L (no) 2001-12-21
AR030551A1 (es) 2003-08-27
DE60122252T2 (de) 2007-07-05
US6399650B2 (en) 2002-06-04
CN1362877A (zh) 2002-08-07
NO321911B1 (no) 2006-07-17
DE60122252D1 (de) 2006-09-28
JP2003523385A (ja) 2003-08-05
EP1171123A1 (en) 2002-01-16
US6423739B1 (en) 2002-07-23
HK1047038A1 (zh) 2003-02-07
CA2368352A1 (en) 2001-08-30
ATE336246T1 (de) 2006-09-15
TWI289060B (en) 2007-11-01
CA2368352C (en) 2009-11-10
NO20015162D0 (no) 2001-10-22
MXPA01010749A (es) 2002-08-20
EP1171123B1 (en) 2006-08-16
US20010051653A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
DOP2008000001A (es) Oxazolidinonas substituidas y su uso
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
EP1680110A4 (en) DAILY DOSED FORM OF TROSPIUM
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
EP1389468A4 (en) COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
BR0208488A (pt) Agonistas de kapa-opiato para o tratamento de doenças da bexiga
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
JP2004503471A5 (enExample)
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DK93091D0 (da) Laegemidler til behandling af toxoplasmose
RU2005131943A (ru) Лечебные и/или профилактические средства для хронических болезней кожи
HU9201295D0 (en) Medical preparations for treating cryptosporidiosys
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]